IL-12 Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

IL-12 Inhibitor Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

IL-12 Inhibitors are a class of pharmaceuticals designed to target and inhibit the activity of interleukin-12 (IL-12); a cytokine involved in the immune response. By blocking IL-12, these inhibitors aim to modulate the immune system and reduce inflammation. IL-12 Inhibitors find application in the treatment of various inflammatory and autoimmune diseases, including psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis, among others. According to the World Health Organization (WHO), psoriasis affects approximately 2-3% of the global population, with higher prevalence rates reported in Europe and North America. In Europe, an estimated 1.5% of the population is affected by rheumatoid arthritis, and it is a leading cause of disability. Crohn's disease, a chronic inflammatory bowel disease, affects approximately 1.5 million people in Europe and 1-1.3 million people in the United States. Multiple sclerosis is estimated to affect around 700,000 people in Europe and 1 million people in the United States, as per the respective countries' health authorities.

The growth of the IL-12 Inhibitor market is driven by several factors. These include the increasing understanding of the role of IL-12 in inflammatory and autoimmune diseases, a growing patient population, advancements in research and development, and the introduction of novel IL-12 inhibitors drugs with improved efficacy and safety profiles. Companies such as AbbVie, Madrigal Pharma, VBL Therap, AI Therap, Akesobio, Ventyx Biosci, Amgen, Alvotech, Samsung, Pfizer, Antisoma, ESSA Pharma, Fuji Pharma, Cipla, Teva cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, VBL Therapy is currently conducting a clinical trial of the drug VB-201 for the treatment of psoriasis.

Key Developments:

  • In Sep 2022, AI Therapeutics in collaboration with Yale University completed a phase II trial of Apilimod dimesylate in COVID-2019 infections in the USA.
  • In July 2022, Akeso completed the phase III trial of Ebdarokimab in Plaque psoriasis.

Approved IL-12 Inhibitor molecules

  • Ozespa (briakinumab)

IL-12 Inhibitor Pipeline Molecules

  • Apilimod (STA-5326)
  • VB-201
  • Apilimod dimesylate (AIT-101)
  • Ebdarokimab (AK101)
  • VTX958
  • ABP 654 (ustekinumab biosimilar)
  • AVT04 (ustekinumab biosimilar)
  • BAT2206 (ustekinumab biosimilar)
  • CT-P43 (ustekinumab biosimilar)
  • SB17 (ustekinumab biosimilar)
  • AN2898
  • AS1409
  • BFI-751 (ustekinumab biosimilar)
  • Bmab1200 (ustekinumab biosimilar)
  • DMB-3115 (ustekinumab biosimilar)
  • FYB202 (ustekinumab biosimilar)
  • NeuLara (ustekinumab biosimilar)
  • RT-111 (ustekinumab biosimilar)
  • Hypochlorous acid (PR022)  

Clinical Activity and Development of IL-12 Inhibitor

In the IL-12 Inhibitor space, more than 10 companies are conducting more than 50 clinical trials in this category of drugs. For instance,

  • In April 2023, AI Therapeutics released pharmacodynamics data from a phase IIa trial of Apilimod dimesylate in Amyotrophic Lateral Sclerosis.
  • In Oct 2022, VBL Therapeutics completed a phase II trial of VB-201 for COVID-2019 infections in Israel.

Product Name

Total Studies

Apilimod (STA-5326)

7

VB-201

6

Apilimod dimesylate (AIT-101)

4

Ebdarokimab (AK101)

4

VTX958

3

ABP 654 (ustekinumab biosimilar)

2

AVT04 (ustekinumab biosimilar)

2

BAT2206 (ustekinumab biosimilar)

2

CT-P43 (ustekinumab biosimilar)

2

JNJ-26483327

1

Target Indication Analysis of IL-12 Inhibitor

IL-12 Inhibitors are targeted therapies that specifically inhibit the activity of interleukin-12 (IL-12), a cytokine involved in the immune response. By blocking IL-12, these inhibitors aim to treat a range of inflammatory and autoimmune diseases, including psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis. IL-12 plays a crucial role in promoting inflammation and immune responses, and its excessive activity is implicated in the pathogenesis of these conditions. IL-12 Inhibitors, by modulating the immune system and reducing inflammation, aim to alleviate symptoms, slow disease progression, and improve the quality of life for patients suffering from these target indications.

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

Frequently Asked Questions

IL-12 Inhibitor drugs are used in the management of a range of inflammatory and autoimmune diseases, including psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis.

The growth of the IL-12 Inhibitor market is primarily driven by several key factors. Firstly, the increasing understanding of the role of IL-12 in inflammatory and autoimmune diseases has heightened the demand for targeted therapies. IL-12 Inhibitors offer a specific and effective treatment option by modulating the immune response and reducing inflammation. Secondly, the growing patient population suffering from these diseases, coupled with the need for long-term management, drives the demand for IL-12 Inhibitors.

The major players in this space are AbbVie, Madrigal Pharma, VBL Therap, AI Therap, Akesobio, Ventyx Biosci, Amgen, Alvotech, Samsung, Pfizer, Antisoma, ESSA Pharma, Fuji Pharma, Cipla, Teva. a.

The market for IL-12 Inhibitors faces restraints due to potential side effects associated with long-term usage, such as increased risk of infections and autoimmune reactions. Additionally, the high cost of IL-12 Inhibitors and limited reimbursement coverage may hinder their widespread adoption and accessibility in the market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

Key Market Players

  • Madrigal Pharma
  • Samsung
  • Pfizer
  • Antisoma
  • VBL Therap
  • AI Therap
  • Akesobio
  • ESSA Pharma
  • Fuji Pharma
  • Cipla
  • Teva
  • Ventyx Biosci
  • Amgen
  • Alvotech

Related Industry Reports